Restricted accessResearch articleFirst published online 2014-05
Suppression of Neovascularization of Donor Corneas by Transduction with Equine Infectious Anemia Virus-Based Lentiviral Vectors Expressing Endostatin and Angiostatin
Corneal transplantation is the oldest and one of the most successful transplant procedures with a success rate in many studies in excess of 90%. The high success rate is mainly attributable to the relatively immune-privileged status of the eye and the fact that the cornea is largely avascular. However, the success rate in patients with failed grafts is much lower such that regrafting is frequently the top indication for corneal transplantation in many centers. Neovascularization is the most important risk factor for rejection, as it allows access of the immune system to the donor tissue, compromising immune privilege of the graft/eye. We have developed a process to modify donor corneal tissue to prevent rejection by a single exposure to a gene therapy vector before surgery (EncorStat®). The vector used is based on clinically relevant equine infectious anemia virus (EIAV)-derived lentiviral platform and contains genes for two potently angiostatic genes, endostatin and angiostatin. We show that incubation of rabbit, primate, and human corneal tissue with the EIAV vector mediates strong, stable expression in the corneal endothelium. We have optimized this process to maximize transduction and, once this is complete, maximize the removal of free vector before transplant. Rabbit corneas treated with two different antiangiogenic expression vectors (EIAV-EndoAngio and to a lesser extent EIAV-Endo:k5) significantly suppressed neovascularization in a rabbit model of corneal rejection. As a result, corneal opacity, edema, and inflammatory infiltrates were reduced in these corneas. This study demonstrates that angiogenesis is a suitable target to prevent corneal rejection, and provides the first proof-of-concept data for the development of EncorStat, an ex vivo gene therapy treatment to prevent corneal rejection.
Get full access to this article
View all access options for this article.
References
1.
AnshuA., LimL.S., HtoonH.M., et al. (2011). Postoperative risk factors influencing corneal graft survival in the Singapore Corneal Transplant Study. Am. J. Ophthalmol., 151, 442–448.e1.
2.
ArmitageW.J. (2011). Preservation of human cornea. Transfus. Med. Hemother., 38, 143–147.
3.
AzarD.T. (2006). Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc., 104, 264–302.
4.
BachmannB., TaylorR.S., and CursiefenC. (2010). Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology, 117, 1300–1305.e7.
5.
BalagganK.S., BinleyK., EsapaM., et al. (2006). Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J. Gene Med., 8, 275–285.
6.
BarciaR.N., DanaM.R., and KazlauskasA. (2007). Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am. J. Transplant., 7, 2082–2089.
7.
BeutelspacherS.C., ArdjomandN., TanP.H., et al. (2005). Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction. Exp. Eye Res., 80, 787–794.
8.
BeutelspacherS.C., PillaiR., WatsonM.P., et al. (2006). Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur. J. Immunol., 36, 690–700.
9.
BinleyK., WiddowsonP., KelleherM., et al. (2012). Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat, for age-related macular degeneration. Hum. Gene Ther., 23, 980–991.
10.
BlezingerP., WangJ., GondoM., et al. (1999a). Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat. Biotechnol., 17, 343–348.
11.
BlezingerP., YinG., XieL., et al. (1999b). Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models. Angiogenesis, 3, 205–210.
12.
BoimerC., LeeK., SharpenL., et al. (2011). Evolving surgical techniques of and indications for corneal transplantation in Ontario from 2000 to 2009. Can. J. Ophthalmol., 46, 360–366.
13.
CelikI., SurucuO., DietzC., et al. (2005). Therapeutic efficacy of endostatin exhibits a biphasic dose-response curve. Cancer Res., 65, 11044–11050.
14.
ComerR.M., KingW.J., ArdjomandN., et al. (2002). Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Invest. Ophthalmol. Vis. Sci., 43, 1095–1103.
15.
EllisS., MiskinJ., BinleyK., et al. (2012). LentiVector, a highly effective equine infectious anaemia virus-based lentiviral gene therapy platform for ocular disease. ARVO Meet Abstr., 53, 1912.
GongN., PleyerU., VogtK., et al. (2007). Local overexpression of nerve growth factor in rat corneal transplants improves allograft survival. Invest. Ophthalmol. Vis. Sci., 48, 1043–1052.
18.
HaraH., and CooperD.K. (2011). Xenotransplantation—the future of corneal transplantation?. Cornea, 30, 371–378.
19.
HongS.Y., LeeM.H., KimK.S., et al. (2004). Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model. World J. Gastroenterol., 10, 1191–1197.
20.
JinX., BooksteinR., WillsK., et al. (2001). Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther., 8, 982–989.
21.
KampikD., AliR.R., and LarkinD.F. (2011). Experimental gene transfer to the corneal endothelium. Exp. Eye Res., 95, 54–59.
22.
KimJ.H., KimJ.C., ShinS.H., et al. (1999). The inhibitory effects of recombinant plasminogen kringle 1–3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp. Mol. Med., 31, 203–209.
23.
KlebeS., SykesP.J., CosterD.J., et al. (2001). Prolongation of sheep corneal allograft survival by ex vivo transfer of the gene encoding interleukin-10. Transplantation, 71, 1214–1220.
24.
KlebeS., CosterD.J., SykesP.J., et al. (2005). Prolongation of sheep corneal allograft survival by transfer of the gene encoding ovine IL-12-p40 but not IL-4 to donor corneal endothelium. J. Immunol., 175, 2219–2226.
25.
Konig MeredizS.A., ZhangE.P., WittigB., et al. (2000). Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation. Graefes Arch. Clin. Exp. Ophthalmol., 238, 701–707.
26.
LaiL.J., XiaoX., and WuJ.H. (2007). Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J. Biomed. Sci., 14, 313–322.
27.
MaD.H., ChenJ.K., ZhangF., et al. (2006). Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog. Retin. Eye Res., 25, 563–590.
28.
MurthyR.C., McfarlandT.J., YokenJ., et al. (2003). Corneal transduction to inhibit angiogenesis and graft failure. Invest. Ophthalmol. Vis. Sci., 44, 1837–1842.
29.
NakaoS., Hafezi-MoghadamA., and IshibbashiT. (2012). Lymphatics and lymphangiogenesis in the eye. J. Ophthalmol., 2012, 783163.
30.
NoroT., MiyakeK., Suzuki-MiyakeN., et al. (2004). Adeno-associated viral vector-mediated expression of endostatin inhibits tumor growth and metastasis in an orthotropic pancreatic cancer model in hamsters. Cancer Res., 64, 7486–7490.
31.
OhlmannA.V., OhlmannA., Welge-LussenU., et al. (2005). Localization of collagen XVIII and endostatin in the human eye. Curr. Eye Res., 30, 27–34.
PatelS.V. (2011). Graft survival after penetrating keratoplasty. Am. J. Ophthalmol., 151, 397–398.
34.
PereraC., JhanjiV., and VajpayeeR.B. (2011). Factors influencing outcomes of the treatment of allograft corneal rejection. Am. J. Ophthalmol., 152, 358–363.e2.
35.
PleyerU., BertelmannE., RieckP., et al. (2000). Survival of corneal allografts following adenovirus-mediated gene transfer of interleukin-4. Graefes Arch. Clin. Exp. Ophthalmol., 238, 531–536.
36.
PonnazhaganS., MahendraG., KumarS., et al. (2004). Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res., 64, 1781–1787.
37.
RahmanI., HuangM.C., CarleyF., et al. (2010). The influence of donor and recipient factors in allograft rejection of the human cornea. Eye (Lond.), 24, 334–339.
38.
RocherN., Behar-CohenF., PournarasJ.A., et al. (2011). Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. Mol. Vis., 17, 104–112.
39.
SabanD., DastjerdiM., and DanaR. (2010). Chapter 8: corneal graft rejection. In Ocular Disease: Mechanisms and Management. LevinL.A. and AlbertD.M., eds. (Saunders, New York, NY), pp. 56–63.
40.
SauterB., MartinetO., ZhangW., et al. (2000). Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc. Natl. Acad. Sci. USA, 97, 4802–4807.
41.
ShaoX.J., and ChiX.Y. (2005). Influence of angiostatin and thalidomide on lymphangiogenesis. Lymphology, 38, 146–155.
42.
ShiW., TeschendorfC., MuzyczkaN., et al. (2002). Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther., 9, 513–521.
43.
ShiW., TeschendorfC., MuzyczkaN., et al. (2003). Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother. Oncol., 66, 1–9.
44.
ShinS.H., KimJ.C., ChangS.I., et al. (2000). Recombinant kringle 1–3 of plasminogen inhibits rabbit corneal angiogenesis induced by angiogenin. Cornea, 19, 212–217.
45.
SubramanianI.V., GhebreR., and RamakrishnanS. (2005). Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther., 12, 30–38.
46.
Tjin Tham SjinR.M., NaspinskiJ., BirsnerA.E., et al. (2006). Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther., 13, 619–627.
47.
VenkataramanB. (2008). Countries make push to increase eye donors. The New York Times, July15, 2008.
48.
WangX., AppukuttanB., OttS., et al. (2000). Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. Gene Ther., 7, 196–200.
49.
WenX.Y., BaiY., and StewartA.K. (2001). Adenovirus-mediated human endostatin gene delivery demonstrates strain-specific antitumor activity and acute dose-dependent toxicity in mice. Hum. Gene Ther., 12, 347–358.
50.
WilliamsK., and CosterJ. (1993). Clinical and experimental aspects of corneal transplantation reviews. Transplant. Rev., 7, 44–64.
51.
WilliamsK.A., LoweM., BartlettC., et al. (2008). Risk factors for human corneal graft failure within the Australian corneal graft registry. Transplantation, 86, 1720–1724.
52.
WongL.-F., YipP., BattagliaA., et al. (2006). Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat. Neuro., 9, 243–250.
53.
ZhangE.P., FrankeJ., SchroffM., et al. (2003). Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice. Graefes Arch. Clin. Exp. Ophthalmol., 241, 921–926.
54.
ZhangX., XuJ., LawlerJ., et al. (2007). Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin. Cancer Res., 13, 3968–3976.
55.
ZhuoW., ChenY., SongX., et al. (2011). Endostatin specifically targets both tumor blood vessels and lymphatic vessels. Front. Med., 5, 336–340.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
